
Ron S. Gejman MD, PhD
@rongejman
Heme/Onc fellow @columbiacancer. Former IM @brighamwomens @harvardmed. MD/PhD @TriIMDPhD @MSKCancerCenter.
ID: 115166941
http://ron.gejman.com 17-02-2010 20:44:39
3,3K Tweet
1,1K Followers
3,3K Following



Well worth reading the N&V here and the paper from Peter Westcott. Neoantigen clonal heterogeneity has an important impact on tumor immunogenicity—and therefore on tumor responsiveness to immunotherapy.




Why has the proportion of cancers that could be prevented by known means not increased over 40 years? Paul Brennan Bert Hofman & I suggest it could be that exposures are ubiquitous link.springer.com/article/10.100… (a cancer-focused academic.oup.com/ije/article/40… update plus Richard Peto homage)






Perhaps cars and trucks should also be discouraged from driving in the city on days with poor air quality Governor Kathy Hochul


Excellent piece from my friend Jordan Hirsch. The culture of innovation in the US is among the best in the world. Just look at the incredible and rapid progress in tech, science and medicine. We need to remember these strengths even in times of political turmoil.


Congratulations to Lindsay Caprio somnath tagore, many people in my group, and outstanding collaborators Denis Kresimir Bestak Fei Chen Lab Caris Life Sciences and many others on this paper, profiling non-small cell lung cancer brain metastases nature.com/articles/s4159…
